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Abstract
Background: Protein HMGB1, an abundant nuclear non-histone protein that interacts with DNA and has an architectural
function in chromatin, was strikingly shown some years ago to also possess an extracellular function as an alarmin and a
mediator of inflammation. This extracellular function has since been actively studied, both from a fundamental point of view
and in relation to the involvement of HMGB1 in inflammatory diseases. A prerequisite for such studies is the ability to detect
HMGB1 in blood or other biological fluids and to accurately measure its concentration.
Methodology/Principal Findings: In addition to classical techniques (western blot, ELISA) that make use of specific anti-
HMGB1 antibodies, we present here a new, extremely sensitive technique that is based on the fact that hemicatenated DNA
loops (hcDNA) bind HMGB1 with extremely high affinity, higher than the affinity of specific antibodies, similar in that respect
to DNA aptamers. DNA-protein complexes formed between HMGB1 and radiolabeled hcDNA are analyzed by
electrophoresis on nondenaturing polyacrylamide gels using the band-shift assay method. In addition, using a simple
and fast protocol to purify HMGB1 on the basis of its solubility in perchloric acid allowed us to increase the sensitivity by
suppressing any nonspecific background. The technique can reliably detect HMGB1 at a concentration of 1 pg per microliter
in complex fluids such as serum, and at much lower concentrations in less complex samples. It compares favorably with
ELISA in terms of sensitivity and background, and is less prone to interference from masking proteins in serum.
Conclusion: The new technique, which illustrates the potential of DNA nanoobjects and aptamers to form high-affinity
complexes with selected proteins, should provide a valuable tool to further investigate the extracellular functions of HMGB1
and its involvement in inflammatory pathologies.
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Introduction
Protein HMGB1 (High Mobility Group B1) was initially
discovered as one of the most abundant nuclear non-histone
proteins in eukaryotic cells. After its discovery [1] it was mostly
studied for its interactions with DNA and its function in the
nucleus as a constituent of chromatin [2], and as the prototype of
the HMG-box family of proteins, many of which are implicated in
the control of differentiation or development [3]. For many years
the extranuclear functions of HMGB1 were little studied (with the
notable exception of studies on amphoterin, the other name of
HMGB1, by Rauvala and coworkers [4]), until Wang et al. [5]
strikingly showed that, in addition to its nuclear functions,
HMGB1 was involved in sepsis as a late mediator of endotoxin
lethality in mice. HMGB1 has since been implicated in many
other pathologies including arthritis and cancer, and many works
have studied the function of extracellular HMGB1 in infectious
and inflammatory disorders, its interest as a potential therapeutic
target, and its role as a messenger («alarmin») when released from
the nuclei of necrotic cells (for recent reviews see e.g. [6–10]).
Experimentally, most of these studies require the ability to
detect HMGB1 and measure its concentration in cell culture
medium or in biological samples, most frequently blood plasma or
serum. Initially the western blotting technique was most widely
used [5,11,12], while more recently ELISA have become available
[13–15]. In both techniques the detection of HMGB1 rests on the
high specificity and affinity of antibodies directed against
HMGB1. However antibodies are not the only macromolecules
with very high affinity for HMGB1, as this protein also presents a
strong affinity for specific alternative conformations of DNA.
Indeed, since the first observation of HMGB1 binding to DNA
cruciforms [16], several DNA substrates with higher and higher
affinities have been identified, culminating with DNA minicircles
of less than 100 bp [17–19], (dissociation constant Kd ,100 pM),
and with hemicatenated DNA loops (hcDNA) [20], which
presently constitute the HMGB1 substrate with the highest affinity
known, with a dissociation constant Kd,0.15 pM [21,22]. The
structure of hemicatenated DNA loops is schematically represent-
ed in Figure 1A; they consist in a DNA loop maintained at its base
by a DNA hemicatenane, i.e. the junction of two double-stranded
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between the two strands of the other, and reciprocally, forming a
DNA knot [20] that could be visualized by atomic force
microscopy (AFM) [23]. Figure 1B shows that this structure,
formed here with a 120 bp DNA fragment and analyzed on a non-
denaturing polyacrylamide gel, migrates slightly more slowly than
linear DNA and associates with HMGB1 to form very stable
complexes that can easily be detected on polyacrylamide gels due
to their reduced mobility as compared to the unbound
hemicatenated probes.
In addition to studying the role of hemicatenanes and their
interactions with HMGB1 in genome structure and function [24],
we also considered taking advantage of the extremely high affinity
of hcDNA for HMGB1, superior to the average affinity of specific
antibodies [25], to detect HMGB1 and to measure its concentra-
tion in biological fluids. Here we show that HMGB1 can be
detected at extremely low concentrations in all kinds of samples,
especially in serum. The property of HMGB1 to be soluble in acid
allowed us to design a simple and rapid protocol to purify it from
most other serum proteins, reducing the nonspecific background
and greatly increasing the sensitivity of the technique. Finally we
discuss the characteristics of this new technique and its advantages
relative to techniques such as ELISA that are based on the binding
of HMGB1 to specific antibodies.
Materials and Methods
HMGB1
Protein HMGB1 of mammalian origin, either from rat liver
nuclei or from cultured cells (human HeLa or monkey CV1 cell
lines), was purified by chromatography as described [26].
Alternatively HMGB1 was expressed in E. coli as a fusion protein
with a N-terminal (His)6 tag, using a plasmid construct made by
inserting the rat HMGB1 gene into expression vector pET15b
[22]. The His-tagged protein was purified by affinity chromatog-
raphy on Ni-NTA, followed by ion exchange chromatography on
a mono P column [27]. The concentration of the purified proteins
was determined spectrophotometrically and further confirmed by
electrophoresis on SDS-polyacrylamide gels, coomassie blue
staining, and comparison with samples containing known amounts
of a control protein [22]. Measurement of HMGB1 concentration
by enzyme-linked immunosorbent assay (ELISA) was performed
using the HMGB1 ELISA kit from Shino-Test Corporation,
Japan, according to the manufacturer’s protocol.
Preparation of hcDNA
hcDNA was prepared from a DNA fragment containing a tract
of poly(CA)?poly(TG), essentially as described previously [20]. In
brief, the fragment is heat-denatured and allowed to renature in
the presence of HMGB1; shifted reassociation of the repetitive
sequences leads to DNA folding into a hemicatenated loop.
In practice, the DNA fragment used to prepare hcDNA originated
from plasmid pE10 (accession X96980), a pUC19 derivative
containing a 62 bp tract of the repetitive DNA sequence poly(-
CA)?poly(TG). A 120 bp fragment containing the repetitive tract was
prepared by digestion of this plasmid with EcoRI and ClaI,
polyacrylamide gel purified, dephosphorylated, and end-labeled with
32P using polynucleotide kinase and [c-
32P]ATP (6 000 Ci/
mmol<220 000 Bq/pmol), following standard protocols.
For the shifted strand reassociation leading to hcDNA
formation, two 1.5 mL tubes are prepared, the first tube
containing ,200 ng of labeled DNA fragment in 50 mLT E
(10 mM Tris-HCl, 1 mM EDTA, pH 7.5), the second tube
containing 20 mLo f1 0 6 buffer (500 mM NaCl, 150 mM Tris-
HCl pH 7.5, 10 mM DTT, 1 mM EDTA, 1% Triton X-100),
100 ng bacteriophage lambda DNA, 1 mg HMGB1, plus TE
buffer to a final volume of 150 mL. The DNA fragment present in
the first tube is denatured by a 3 min incubation in a water bath at
100u, then transferred and mixed as quickly as possible to the
content of the second tube and incubated 30 min at 37u.
The hcDNA-HMGB1 complex formed, which may contain up to
25–30% of the total labeled DNA, is purified by electrophoresis on a
4% polyacrylamide gel (see below) and electroelution. HMGB1 is
removed by a2 min extraction with chloroform atroom temperature
in the presence of 1 M NaCl and 1% SDS, followed by 5 min
centrifugation at 13 0006ga t4 u. The aqueous phase is recovered
and hcDNA precipitated with 2.5 vol. ethanol in the presence of
linear polyacrylamide carrier [28], redissolved in TE +50 mM NaCl,
a n ds t o r e da t4 u in low-binding polypropylene tubes.
Comments. The presence of HMGB1 during the formation
process of hcDNA is required to increase DNA flexibility and
facilitate the formation of a loop. Whether HMGB1 originates
from mammalian cells or is a His-tagged recombinant protein
makes no significant difference.
The denatured DNA must be transferred as quickly as possible
to the solution containing HMGB1, as premature reassociation of
DNA strands would reduce the yield of hcDNA. The specific
activity of the probe does not depend on this yield, however, but
remains equal to the specific activity of the labeled DNA fragment
used to prepare hcDNA.
The presence of competitor DNA is required to avoid smearing
on the preparative gel due to non-specific binding of HMGB1 to
labeled DNA. This is particularly important when His-tagged
HMGB1 is used, as the affinity of the tagged protein for linear
DNA is somewhat higher than the affinity of HMGB1 from
mammalian origin (C.G. and F.S., unpublished data).
Figure 1. (A) Schematic representation of a hemicatenated DNA loop
(hcDNA). A double-stranded DNA fragment is folded into a loop
maintained at its base by a hemicatenane, i.e. the junction of two
double-stranded DNA molecules in which one of the strands of one
duplex passes between the two strands of the other duplex, and
reciprocally. (B) Gel electrophoresis of hcDNA and its complexes with
HMGB1. A 120 bp DNA fragment was
32P end-labeled and used to
prepare hcDNA, which was analyzed by electrophoresis on a 4%
polyacrylamide gel. hcDNA (left lane) migrates as several bands as a
function of the size and of the location of the loop along the structure.
Addition of the indicated amounts of pure HMGB1 results in the
formation of DNA-protein complexes that migrate as two retarded
bands, C1 and C2, corresponding to the binding of one or two HMGB1
molecules per hemicatenane, respectively. For the low protein
concentrations the amount of shifted hcDNA is proportional to the
protein amount, with a lower detection limit of 0.04 pg HMGB1 [21]. At
high protein concentrations, when all the hcDNA probe is complexed
with HMGB1, the amount of hcDNA becomes limiting and further
addition of HMGB1 does not modify the band pattern.
doi:10.1371/journal.pone.0002855.g001
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of any other DNA with a high and well-defined molecular weight,
avoids any contamination of hcDNA with short fragments of
competitor DNA. However such a contamination would have no
visible effect on the band shift assay, it is therefore possible to use
any common DNA such as salmon sperm or E. coli DNA as
competitor.
hcDNA-HMGB1 interactions
Incubations are performed in low-binding polypropylene tubes
containing labeled hcDNA (,5000 cpm) in 25 mLo f5 0 m M
NaCl, 25 mM Tris-HCl pH 7.5, 1 mM DTT, 1 mM EDTA,
0.1% Triton X-100, 100 mg/mL BSA, 2% glycerol, plus unlabeled
competitor DNA. Double-stranded competitor was full-length
DNA from bacteriophage lambda, but any double-stranded DNA
would be equally efficient. Single-stranded competitor was heat-
denatured DNA from E. coli; here again any DNA can be used
provided it is of sufficient complexity to avoid its fast renaturation
during incubation. Unless otherwise noted, the amounts of
competitor DNA used are the following. With pure HMGB1: no
competitor. With samples containing low concentrations of
proteins, such as cell-culture medium: 100 ng double strand
+10 ng single strand DNA per sample. With serum (or plasma) not
treated with perchloric acid: 2 mg double strand +1 mg single
strand. With serum after perchloric acid precipitation: 100 ng
double strand, no single strand.
To hcDNA in the above solution, a given volume, 1 to 2 mL, of
sample to be assayed is added and gently mixed. After 20 min of
incubation at 37u the samples are loaded onto a polyacrylamide
gel. For quantitative measurement of HMGB1 concentration,
calibration curves are obtained using serial dilutions of a known
amount of HMGB1 in 50 mM NaCl, 25 mM Tris-HCl pH 7.5,
1 mM DTT, 0.1 mM EDTA, 0.1% Triton-X100, 100 mg/mL
BSA, 15% glycerol. Triton-X100 and BSA are both required for
dilution of HMGB1, even when working with low-binding
polypropylene tubes, to avoid any loss of HMGB1 on tube walls
and to ensure that the HMGB1 concentrations of the serial
dilutions are as accurate as possible. Dilute HMGB1 solutions are
stored frozen at 280u, and can be thawed and frozen several times
with no significant loss of hcDNA-binding activity. The calibration
curves were found to depend on two parameters only: the amount
of hcDNA probe per sample is obviously the most important
parameter; second, as HMGB1 presents a weak but detectable
affinity for single-stranded DNA, a decrease of the signal is
observed in the presence of high concentrations of single-stranded
competitor.
The anti-HMGB1 antibody used to supershift the HMGB1-
hcDNA complexes was affinity-purified rabbit anti-HMG1
polyclonal antibody from BD Pharmingen (now discontinued).
Band-shift assay
In initial experiments [20,22], the complexes of HMGB1 with
hcDNA were analyzed by electrophoresis on 4% polyacrylamide
gels in a low-ionic strength buffer (6.7 mM Tris, 3.3 mM Na
Acetate, 1 mM EDTA, pH 7.8), at 4u, with buffer recirculation, a
gel system often used to stabilize DNA-protein interactions. Later
we observed that the hcDNA-HMGB1 complexes were so stable
that they could be analyzed with identical results in 4%
polyacrylamide gels in 0.56 TBE buffer at room temperature
without buffer recirculation, a much more convenient gel system.
Consequently complexes are now routinely analyzed at room
temperature on 4% polyacrylamide gels (acrylamide:bis-acrylamide
29:1) in 0.56TBE buffer at a voltage of ,8 V/cm, with a 10 min
prerun and 3 hr of migration for a 15 cm gel. After electrophoresis
the gels are dried on a sheet of Whatman 3 MM paper and exposed
either on autoradiographic film or on a phosphorimager screen for
quantification of the radioactivity in the bands.
Calibration of the technique is performed with a series of
samples containing known amounts of pure HMGB1, assayed in
parallel under strictly identical experimental conditions. After
exposure of the gel to autoradiographic film or phosphorimager
screen, the intensities of the bands are measured with ImageJ or
ImageQuant software, respectively. A calibration curve is drawn
by plotting the percentage of shifted material (bands C1+C2) as a
function of the amount of HMGB1 on a semi-logarithmic scale. A
second calibration curve, which gives useful information for high-
concentration samples when 100% of hcDNA is shifted, is drawn
by plotting the ratio of intensities of peaks C2 and C1 as a function
of HMGB1 amount.
Viral infections
Human epithelial cells of genital origin (HEC-1) were grown in
RPMI medium supplemented with 5% fetal calf serum (or 1%
serum during viral infection), at 37uC in the presence of 5% CO2
until sub-confluence. Infections were performed in 6-well plates
with a clinical isolate of Herpes Simplex Virus type 2 at various
multiplicities of infection. Culture medium was collected at the
indicated times after infection and clarified by centrifugation
(13 0006g, 10 min, 4uC) before analysis.
Perchloric acid precipitation
The majority of serum proteins other than HMGB1 can be
removed by precipitation in the presence of 3% perchloric acid
(PCA) as follows.
A stock solution of 13.7% PCA is prepared by mixing 1.26 vol.
of 70% PCA with 8.69 vol. H2O. These values, especially the
value of 13.7% for the PCA stock, have been derived from the
tables of perchloric acid density as a function of concentration [29]
so as to yield a final PCA concentration of 3% upon five-fold
dilution. The PCA stock solution is stored in an air-tight brown-
glass bottle at room temperature.
To 1 vol. of serum (or other sample to be analyzed) on ice, J
vol. PCA at 13.7% is added and mixed. The 3% PCA
concentration results in the instant formation of a very abundant
precipitate. The sample is immediately centrifuged for 5 min. at
13 0006ga t4 u in a benchtop centrifuge. A known volume of the
supernatant, which contains HMGB1, is collected and neutralized
by addition of 1/5 its volume of 1.5 M NaOH.
As the precipitation-neutralization process results in a 50%
volume increase due to the addition of reagents, 1.5 mL of the
neutralized supernatant is assayed to measure HMGB1 concen-
tration in 1 mL of serum.
Results
The band-shift assay is an extremely sensitive technique that is
particularly suited to study high-affinity DNA-protein interactions
such as HMGB1 binding to hcDNA [21,22]. The gel shown in
Figure 1B illustrates the results obtained with a hcDNA probe
prepared from a DNA fragment
32P-end-labeled to high specific
activity. With serial dilutions of a highly purified preparation of
HMGB1 from mammalian cells, one can detect 0.04 pg of
HMGB1, an amount that gives a weak but clearly visible signal.
With 1 pg of protein, more than half of the probe is bound by
HMGB1. Upon further increasing the protein concentration the
signal reaches a plateau when the amount of substrate becomes
limiting, as one hcDNA molecule cannot bind more than two
HMGB1 molecules. Note that in this experiment the labeled
HMGB1 and DNA Hemicatenanes
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at all by HMGB1.
The situation is slightly different when assaying HMGB1 in
culture medium or biological fluids, which contain other proteins
that can interact with DNA. Such proteins result in a non-specific
background that can be very high and obscure any specific signal.
However this background can be decreased or even suppressed by
addition of a large excess of a non-radioactive competitor DNA
thanks to the specificity of the interactions between hcDNA and
HMGB1 (or HMGB2), with a binding constant at least three
orders of magnitude higher than that of any other protein tested
(including hcDNA-specific proteins such as single HMG-box
domains, Sry, or p53 [22]). When present, the non-specific and the
lower-specificity proteins bind to the non-radioactive DNA in
excess, while HMGB1 binds specifically to the labeled hcDNA.
Such conditions were used here to detect HMGB1 in the culture
medium of human epithelial cells infected by Herpes Simplex
Virus type 2 (HSV-2) (Figure 2). The basal level of HMGB1
detected in non-infected cells is due to the necrosis background of
the cultured cells, while its increase in infected cells reflects the
release of HMGB1 secondary to HSV2-induced necrosis (C.B.,
manuscript in preparation). In this experiment the addition of
100 ng non-radioactive competitor double strand DNA plus 10 ng
single strand, i.e. a competitor/hcDNA ratio of about 1000, was
sufficient to eliminate the non-specific noise mostly due to the
presence of fetal calf serum in the medium, allowing us to detect
HMGB1 at a concentration of 1 pg/mL.
In practice, when samples to be tested contain high concentra-
tions of various proteins, the nonspecific background becomes
more difficult to decrease. This is especially true for human serum,
which contains an extremely high protein concentration, about
70 mg/mL. In that case the detection of hcDNA-HMGB1
complexes formed with 1 mL of serum requires the addition of
very large amounts of competitor DNA, 2 mg double-strand plus
1 mg single-strand per sample, such amounts of competitor being
absolutely required to avoid smearing. Despite the fact that the
low-affinity binding of HMGB1 to single-strand DNA results in a
decrease of the signal (as observed when comparing the equivalent
calibration samples in Figs. 1, 2, 3), under such conditions it is
possible to detect 10 pg of HMGB1 per sample (Figure 3A). As can
Figure 2. HMGB1 protein assay in culture medium of epithelial human cells infected by herpes simplex virus type 2. (A) Cell culture
medium assayed at the indicated times after infection. At days 3 and 4, HMGB1 concentration was so high that the hcDNA probe was saturated,
requiring a tenfold dilution of the sample for determination of HMGB1 concentrations (right panel). (B) Gel and calibration curve, obtained with
known amounts of pure HMGB1 under identical conditions.
doi:10.1371/journal.pone.0002855.g002
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and result in a significant background and a decrease of the
amount of probe available to form complexes with HMGB1 (this
appears to be due to the high amount of serum proteins able to
bind single-stranded DNA, combined to the fact that the DNA
double helix is partially unwound in hcDNA with unpaired bases
accessible at the level of the hemicatenane [30]). In short,
optimization of the signal-to-noise ratio was found to require a step
to purify HMGB1 from other serum proteins. An often-used
possibility was to purify HMGB1 by chromatography on ion-
exchange columns (heparin is frequently used for that purpose
[11]), or by removal of high molecular weight proteins by filtration
on membrane (e.g. Centricon) [5]. Instead we took advantage of
the property of HMGB1 to be soluble under acidic conditions,
whereas most proteins precipitate in acid [31]. This striking and
quite unusual property is shared by all proteins of the ‘‘High
Mobility Group’’ by definition, as they were first discovered and
purified based on their solubility in acid [1]. Most serum proteins
instantly form a white precipitate when perchloric acid is added to
serum to a final concentration of 3%, while HMGB1 remains in
solution. After centrifugation the supernatant is recovered,
neutralized with sodium hydroxide, and HMGB1 assayed by
band-shift. Figure 3B shows that identical amounts of HMGB1-
hcDNA complexes are detected before and after PCA treatment,
showing that HMGB1 has quantitatively remained in the
supernatant, with its hcDNA-binding activity fully preserved and
recovered after treatment with perchloric acid, despite the fact that
this is one of the strongest acids known.
The potential of the technique is illustrated in Figure 4 with
serums from patients hospitalized for acute respiratory distress
syndrome with sepsis in the intensive care unit of Saint-Antoine
Hospital in Paris. Two series of tests were made in parallel, the first
one by assaying the serums directly, the second by pretreatment of
the same serums with PCA as described above. Two conclusions
can be drawn: first, with unfractionated serums the technique is
already extremely sensitive as it allows one to detect 10 pg
HMGB1 in a very limited amount of sample (1 ml); second, PCA
pretreatment of the serums generally gives qualitatively similar
results but leads to a striking reduction of the background and to a
tenfold increase in sensitivity, with a detection limit of less than
1 pg HMGB1 per microliter of serum. Despite the small number
of serums tested here, one can already observe the wide variations
of HMGB1 concentration from one patient to another, from
undetectable levels (patients g, j, l) up to more than 1000 pg/mL
(patients e, h, m). One can also note the presence of HMGB1 at
10 pg/mL in the control serum from a healthy individual (serum
a), as was already observed by another method [15].
In parallel, HMGB1 was assayed using a commercial HMGB1-
ELISA kit to compare the two techniques. Result are shown in
Figure 4C, circled points a - o representing the results obtained for
the same 15 serums, plotted on a double logarithmic scale with
band-shift data in abscissa and ELISA in ordinate. Globally the
data obtained by both techniques are in very good agreement,
most of the points lying near the diagonal. Exceptions include low-
concentration samples, lower than 2 pg/mL, for which the ELISA
gives higher values than the band-shift assay. This is very likely due
Figure 3. Detection of HMGB1 in human serum. (A) On the left half of the gel, complexes obtained with increasing amounts of pure HMGB1:
0 pg, 10 pg, 100 pg, 1 ng, 10 ng (competitor DNA: 2 mg double strand plus 1 mg single strand per sample). The next five samples contain the same
amounts of HMGB1 plus an anti-HMGB1 antibody, showing the supershift of the specific complexes (since pure HMGB1 was used here, and as
antibodies were polyclonal and present in excess, the partial supershifting is most likely due to a low or moderate affinity of part of the antibodies).
On the right-hand side of the gel, the same experiment was performed with the same amounts of HMGB1 and competitor DNA mixed with 1 mLo f
serum from a healthy individual. The overall pattern of shifted and supershifted bands is identical, over a background that contains a number of non-
specific extra bands, despite the use of a large amount of nonspecific competitor DNA. (B) Purification of HMGB1 by PCA treatment. The left-hand
part of the gel shows the interactions of hcDNA with the indicated amounts of pure HMGB1, from 1 pg to 100 pg. On the right-hand part of the gel,
samples containing the same concentrations of HMGB1, plus 50 mg/mL BSA to mimic an HMGB1-free serum, were treated with PCA and neutralized
as described in Materials and Methods, then assayed for hcDNA binding. Note that the hcDNA-binding activity is recovered without any loss after the
PCA treatment procedure.
doi:10.1371/journal.pone.0002855.g003
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concentrations. Other exceptions are found at high HMGB1
concentration. Samples e, h, m contain more than 1000 pg/mL
HMGB1 as judged by band-shift assay (Fig. 4B), but ELISA fails to
detect the high concentration in h and m. Similarly sample b also
gives a much lower value by ELISA than by band-shift assay.
Interestingly the three samples, b, h, m, also gave lower results by
band-shift when crude serums were assayed without PCA
Figure 4. HMGB1 assay in serums from patients. (A) without PCA treatment, or (B) after sample purification by PCA treatment. On each gel the
five samples on the left, prepared with known amounts of pure HMGB1, were used to calibrate the method. The 15 serums tested are labeled a-o,
serum a originating from a healthy individual, serums b-o from randomly selected patients in intensive care unit (d,g,h,i,k,l,n: sepsis; b,c,e,f,j,m,o:
septic shock). Note the lower sensitivity, higher background, and non-specific bands (arrowheads) obtained with crude serums, as compared with the
strong increase in sensitivity and marked background decrease after treatment of serums with PCA. (C) Comparison of band-shift assay with ELISA.
Concentrations measured by ELISA are plotted against band-shift assay data obtained after PCA treatment of serums, on a double logarithmic scale.
Each circled letter on the diagram represents the corresponding serum as assayed in (B).
doi:10.1371/journal.pone.0002855.g004
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that interact with HMGB1 and inhibit its binding both to hcDNA
and to antibodies, but are dissociated and most likely precipitated
by PCA. This observation is very similar to those made previously
by Urbonaviciute et al. [15] who showed that serums can contain
factors that mask HMGB1 and interfere strongly with ELISA.
Discussion
The new method of detection of HMGB1, based on its
interactions with hemicatenated DNA loops (hcDNA) as analyzed
by band-shift assay, is particularly sensitive. In complex media
such as serum, after selective removal of most proteins other than
HMGB1 by PCA precipitation, HMGB1 concentrations of 1 pg/
mL or lower can be accurately measured. With specimen
containing low concentrations of proteins, for example with
cerebrospinal fluid or bronchoalveolar lavage (data not shown) or
cell-culture medium, the same sensitivity is obtained without the
need for PCA precipitation.
This method presents several advantages over other techniques.
First, it requires only one microliter of sample per assay, or a few
microliters when the PCA precipitation protocol is used, which
can be particularly useful with samples other than serum/plasma
that may be available in very limited volumes only. Second, the
background of the ELISA technique makes it difficult to accurately
measure HMGB1 concentrations below 5 pg/mL, whereas a
concentration of 1 pg/mL gives a clear specific signal for HMGB1
binding to hcDNA as shown in Figure 4B. Third, several protein
factors present in serum or plasma, including anti-HMGB1
antibodies, have been shown to bind HMGB1 and interfere with
ELISA [15]; this is observed again with some of the samples tested
here, especially those with very high HMGB1 concentrations,
most of which are strongly under-estimated by ELISA. With such
samples the acidic PCA treatment, which dissociates HMGB1-
protein complexes and most likely precipitates the interfering
factors, proves very useful to measure the total HMGB1
concentration. Therefore we wondered whether the PCA
treatment might also be used to prepare samples for ELISA.
However preliminary data (not shown) showed that this treatment
results in a decrease by up to 50% of the ELISA signal. This
decrease is not due to HMGB1 loss during PCA treatment since
no signal decrease is observed for hcDNA binding (Fig. 3B).
Neither is it due to an interference of the perchlorate ions with the
ELISA, as dilution of the samples did not lower the effect (not
shown). Therefore it seems likely that a change in HMGB1
properties occurs upon acidic treatment, as previously observed in
other cases [32–34], and results in a decrease of its affinity for the
antibodies used in the ELISA.
The assay is easy to perform once the radioactive hcDNA probe
is ready for use. A single person with only basic electrophoresis
equipment can assay 20 samples per gel. In addition to its
simplicity, a further advantage of gel electrophoresis, whether
performing band-shift assays like here or SDS gels for western
blots, is that it provides a direct visual control of the background
and of the specificity of the signal. The preparation of
hemicatenanes is the only step of the technique that is not of
common practice. It has now been described in great detail,
however, and should pose no particular difficulties to molecular
biology laboratories. The whole process, DNA fragment labelling
with
32P, hcDNA formation, purification by gel electrophoresis,
and electroelution, can be performed in a day. The labeled
hcDNA preparation can then be used for a full month, with only a
4-fold decrease in specific activity, as each assay only requires a
very small amount of probe (,5000 cpm, i.e. ,100 pg). Using
32P
to label DNA is a well-established, easy to monitor, and
convenient way to obtain probes of very high specific activity,
allowing the detection of minute amounts of material, with the
further advantage that the amount of radiolabeled material in the
bands can quickly and easily be quantified by autoradiography or
with a phosphorimager.
In addition to HMGB1, several other proteins have been found
to bind hcDNA with high affinity. The two other HMGB proteins,
HMGB2 and HMGB3, are extremely similar to HMGB1 both in
terms of sequence and of biochemical properties. HMGB2 has
hcDNA-binding characteristics that are practically undistinguish-
able from those of HMGB1 [21,26], and given the sequence
similarity this is most probably also the case for HMGB3. Whereas
HMGB1 is ubiquitous, HMGB2 and HMGB3 are expressed in
specific organs. In the mouse HMGB2 is primarily found in the
thymus and testes [35], and HMGB3 in bone marrow [36].
HMGB1 is expressed to very high levels and is one of the most
abundant non-histone proteins in the nucleus. In contrast
HMGB2 and HMGB3 are much less abundant than HMGB1
and have not been demonstrated to be significantly present in
serum (see e.g. western blots in [5]). In any case, HMGB1,
HMGB2 and HMGB3 probably share the same extracellular
activity since, in addition to their similarity, the 20 amino-acids
domain of HMGB1 that was shown to be the determinant of its
cytokine activity [37] is 95% conserved in HMGB2, and 90% in
HMGB3.
Other proteins that bind hcDNA with high affinity include
single HMG-box domains and proteins containing the HMG-box
domain of homology such as the sex-determination factor Sry,
tumor suppressor p53, as well as the hcDNA-binding proteins
present in the serum as shown in the present work. However, such
non-HMGB1/2/3 proteins would not be detected by the assay for
several reasons. First, our previous studies have shown that the
affinity of HMGB1 for hcDNA is at least three orders of
magnitude higher than the affinity of single HMG-box domains,
Sry [22], or p53 [38], and that these proteins would be displaced
by the large amount of nonradioactive competitor DNA present in
the assay, as only HMGB1/2/3 remain bound to hcDNA under
the high concentrations of competitor DNA used [22]. Second, as
mentioned above HMGB1 is extremely abundant, whereas p53 or
proteins containing an HMG-box domain are rare. Third, being
soluble in acid is quite exceptional for a protein [31], therefore
most if not all extra proteins would be precipitated by PCA as is
visible in Fig. 4A,B for hcDNA-binding proteins from serum.
As HMGB1 is found methylated, phosphorylated, or acetylated
in some specific cases, one may ask whether modified forms would
be detected with the same yield as the unmodified form. This
question can be asked for all types of assays and clearly deserves
further investigation. However reports on the effects of acetylation
[39,40] or methylation [41] failed to show dramatic changes in
DNA binding properties of modified HMGB1. Furthermore we
have shown that mutations of the intercalating residues of
HMGB1, i.e. the amino-acid residues that have been shown to
be important for specific binding of distorted DNA structures,
have little effect on binding to hcDNA [22]. Therefore it is likely
that post-translational modifications of HMGB1 will not dramat-
ically interfere with its affinity for hcDNA.
We only assayed here a very small series of serums, as a test and
an example to illustrate the potentialities of the technique. A
medically-oriented study using this technique on a large series of
patients with well-defined diseases is now in progress in our
laboratory. For the moment we can only point out the presence of
HMGB1 at a significant concentration (10 ng/mL) in the serum of
a healthy control, and the undetectable levels of HMGB1 in the
HMGB1 and DNA Hemicatenanes
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good agreement with those recently reported by Angus et al. [42],
which suggested that the diagnostic value of assaying HMGB1
concentrations in plasma from patients needed to be studied more
deeply [43].
The technique could be further used to study the binding of
molecules or macromolecules to HMGB1, as it has been strongly
suggested that the extracellular functions of HMGB1 often depend
on its interactions with other molecules, such as bacterial
lipopolysaccharides, phosphatidylserine, CpG DNA, or cytokines
([44–48]; Sylvain Thierry, personal communication). Provided
that their interactions do not interfere with hcDNA binding, the
band-shift assay described here might again constitute a very
sensitive technique to detect HMGB1 partners and to study their
interactions.
This technique is among the first practical uses of a DNA
nanostructure. DNA nanotechnology has been a very active and
promising domain of research, as the properties of DNA are
particularly suited to the production of various structures such as
nanoobjects, DNA arrays, or nanomechanical devices [49].
Similarly, the development of nucleic acid species engineered to
bind various molecular targets is a very active field. These DNA
aptamer structures are usually obtained through several rounds of
selection for the highest possible binding affinities, as in the
SELEX procedure, which confers them very promising therapeu-
tic properties [50]. While initially not a product of SELEX,
hcDNA is a DNA structure very similar to an aptamer that will
help understand the functions of HMGB1. Furthermore, like for
aptamers, the possible therapeutic effect of hcDNA in pathologies
involving HMGB1 will also deserve investigation.
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